DBV Technologies S.A. (LON:0QAJ)
United Kingdom · Delayed Price · Currency is GBP · Price in EUR | Market Cap | 527.38M +34.6% |
| Revenue (ttm) | 2.81M -32.2% |
| Net Income | -156.18M |
| EPS | -0.41 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 2,163 |
| Open | 1.973 |
| Previous Close | 1.968 |
| Day's Range | 1.940 - 2.036 |
| 52-Week Range | 1.534 - 4.460 |
| Beta | -0.21 |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Oct 28, 2026 |
About DBV Technologies
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis. The company’s earlier stage research programs include celiac disease. ... [Read more]
Financial Performance
In 2025, DBV Technologies's revenue was $5.64 million, an increase of 35.77% compared to the previous year's $4.15 million. Losses were -$146.95 million, 29.0% more than in 2024.
Financial numbers in USD Financial StatementsNews
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
DBV Technologies NASDAQ: DBVT is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on whether regulators will accept its biologics li...
DBV Technologies Prepares Peanut Patch Launch as FDA Filing Decision Nears
3 Biopharmaceutical Stocks Bucking the Sell-OffDBV Technologies (NASDAQ:DBVT) is preparing for a potential U.S. launch of its peanut allergy patch for children ages 4 to 7 while awaiting a decision on...
DBV Technologies Transcript: 3rd Annual Guggenheim Healthcare Innovation Conference
VIASKIN showed 47% efficacy on active treatment vs 14% on placebo at 1 year, and the 4–7 BLA is under FDA consideration. Commercial preparations target a 600,000-child peanut-allergy market, with launch expected within weeks after PDUFA.
DBV Technologies to Participate in Upcoming November Investor Conferences
Châtillon, France, November 2, 2026 DBV Technologies to Participate in Upcoming November Investor Conferences DBV Technologies (Euronext: DBV – ISIN: FR0010417345 – Nasdaq Stock Market: DBVT) (the “Co...
DBV Technologies price target lowered to $46 from $51 at Guggenheim
Guggenheim lowered the firm’s price target on DBV Technologies (DBVT) to $46 from $51 and keeps a Buy rating on the shares to reflect a “modest delay” in the BLA…
DBV sinks after warning cash not sufficient to fund operations
Shares of DBV Technologies (DBVT) are sinking after the company said “substantial doubt exists” about its ability to continue as a good concern. In last night’s earnings release, DBV commented:…
DBV Technologies price target lowered to $47 from $55 at Citizens
Citizens lowered the firm’s price target on DBV Technologies (DBVT) to $47 from $55 and keeps an Outperform rating on the shares. DBV’s Viaskin Peanut BLA for ages 4-7 could…
DBV Technologies Report Wider Q3 Loss, Advances Peanut Allergy Patch Toward Potential Launch
(RTTNews) - DBV Technologies (DBVT) reported a wider third-quarter 2026 net loss as it increased spending on clinical development, regulatory submissions and commercial preparations for its VIASKIN Pe...
DBV Technologies (DBVT) Q3 2026 Earnings Call Transcript
Net loss widened to $64.5 million as company scales commercial operations.
What DBV Technologies (DBVT) Said on Its Q3 Earnings Call
DBV Technologies NASDAQ: DBVT said it submitted a biologics license application, or BLA, to the U.S. Food and Drug Administration for its VIASKIN Peanut patch in children ages 4 to 7, while continuing...
DBV Technologies reports Q3 EPS (14c), consensus (15c)
“The third quarter marked a defining step in DBV’s evolution from a clinical-stage company into a commercial organization. With our BLA now submitted for children aged 4 through 7 years,…
DBV Technologies Earnings Call Transcript: Q3 2026
The 4–7-year-old VIASKIN Peanut BLA was submitted, with FDA review and Fareva remediation central to execution. Q3 ended with $165.7M in cash and runway forecast into Q3 2027; a toddler BLA is expected in 2027.
DBV Technologies Earnings release: Q3 2026
DBV Technologies released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
DBV Technologies Quarterly report: Q3 2026
DBV Technologies has published its Q3 2026 quarterly earnings report on October 28, 2026.
DBV Technologies Earnings release: Q3 2026
DBV Technologies released its Q3 2026 earnings on October 28, 2026, summarizing the period's financial results.
DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update
Châtillon, France, October 28, 2026 DBV Technologies Reports Third Quarter 2026 Financial Results and Business Update Submitted the Biologics License Application to U.S. FDA for the VIASKIN® Peanut Pa...
DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026
Châtillon, France, October 27, 2026 DBV Technologies to Report Third Quarter 2026 Financial Results and Business Update on October 28, 2026 Company to host investor conference call and webcast at 5:00...
DBV Seeks FDA Approval For VIASKIN Peanut Patch In Young Children
(RTTNews) - DBV Technologies (DBVT) announced that it has submitted a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children aged 4 through 7 years with peanut allergy....
DBV Submits BLA For VIASKIN Peanut Patch In Children With Peanut Allergy
(RTTNews) - DBV Technologies (DBVT) announced the submission of a Biologics License Application to the U.S. FDA for the VIASKIN Peanut Patch in children aged 4 to 7 years with peanut allergy.
DBV Technologies submits BLA to FDA for Viaskin Peanut Patch
DBV Technologies (DBVT) announced that the company has submitted a Biologics License Application to the U.S. FDA for the Viaskin Peanut Patch in children with peanut allergy aged 4 through…
DBV Technologies S.A.: DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN Peanut Patch in Children Aged 4-7 Years The BLA is supporte...
DBV Technologies Announces Submission of Biologics License Application to U.S. FDA for the VIASKIN® Peanut Patch in Children Aged 4-7 Years
Châtillon, France, September 29, 2026 DBV Technologies Announces Submission of Biologics License Ap p lication to U.S. FDA for the VIASKIN ® Peanut Patch in Children Aged 4-7 Years The BLA is supporte...
DBV Technologies Transcript: H.C. Wainwright 28th Annual Global Investment Conference
VIASKIN Peanut BLA filings are planned for ages 4–7 by end-Q3 2026 and ages 1–3 by year-end 2026. Management targets an internal launch, with cash runway into Q3 2027 and THRIVE focused on potential post-treatment disease modification.
DBV Technologies Transcript: 12th Annual Cantor Fitzgerald Global Healthcare Conference
Epicutaneous immunotherapy for peanut allergy in children shows strong safety, convenience, and long-term efficacy, with 68.2% tolerating full food challenges after three years. Regulatory progress is advanced, and the THRIVE study aims to demonstrate lifelong desensitization in infants.
DBV Technologies S.A.: DBV Technologies to Participate in Upcoming September Investor Conferences
Châtillon, France, September 3, 2026 DBV Technologies to Participate in Upcoming September Investor Conferences DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT) (th...